Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

5.8

Margin Of Safety %

Put/Call OI Ratio

0.26

EPS Next Q Diff

EPS Last/This Y

0.36

EPS This/Next Y

0.16

Price

12.6

Target Price

14

Analyst Recom

1.29

Performance Q

21.13

Relative Volume

0.93

Beta

2.05

Ticker: ADPT




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-15ADPT13.040.080.095230
2025-08-18ADPT12.420.180.922025
2025-08-19ADPT12.570.260.492277
2025-08-20ADPT12.290.280.462372
2025-08-21ADPT12.620.280.002380
2025-08-22ADPT13.010.270.002446
2025-08-25ADPT12.660.270.002436
2025-08-26ADPT12.790.270.002451
2025-08-27ADPT12.970.270.062460
2025-08-28ADPT13.310.260.512525
2025-08-29ADPT13.160.270.332565
2025-09-02ADPT12.840.271.562579
2025-09-03ADPT12.850.280.002587
2025-09-04ADPT13.020.280.122598
2025-09-05ADPT12.850.280.182609
2025-09-08ADPT12.530.270.112604
2025-09-09ADPT12.620.270.162619
2025-09-10ADPT12.430.270.382641
2025-09-11ADPT13.480.270.182636
2025-09-12ADPT12.610.260.062656
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-15ADPT13.038.2- -0.76
2025-08-18ADPT12.418.2- -0.76
2025-08-19ADPT12.568.2- -0.76
2025-08-20ADPT12.288.2- -0.76
2025-08-21ADPT12.6216.7- -0.72
2025-08-22ADPT13.0116.7- -0.72
2025-08-25ADPT12.6616.7- -0.72
2025-08-26ADPT12.8016.7- -0.72
2025-08-27ADPT12.9716.7- -0.72
2025-08-28ADPT13.3016.7- -0.72
2025-08-29ADPT13.1616.7- -0.72
2025-09-02ADPT12.8416.7- -0.72
2025-09-03ADPT12.8516.7- -0.72
2025-09-04ADPT13.0216.7- -0.72
2025-09-05ADPT12.8516.7- -0.72
2025-09-08ADPT12.5416.7- -0.72
2025-09-09ADPT12.6216.7- -0.72
2025-09-10ADPT12.4316.7- -0.72
2025-09-11ADPT13.4916.7- -0.72
2025-09-12ADPT12.6016.7- -0.72
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-15ADPT-16.831.966.84
2025-08-18ADPT-16.833.596.84
2025-08-19ADPT-11.923.596.84
2025-08-20ADPT-11.923.596.84
2025-08-21ADPT-11.923.596.84
2025-08-22ADPT-8.653.596.84
2025-08-25ADPT-8.65-2.316.84
2025-08-26ADPT-8.65-2.316.84
2025-08-27ADPT-8.65-2.316.16
2025-08-28ADPT-8.65-2.316.16
2025-08-29ADPT-8.65-2.316.16
2025-09-02ADPT-8.65-2.316.16
2025-09-03ADPT-8.65-2.316.16
2025-09-04ADPT-8.65-2.316.16
2025-09-05ADPT-8.65-2.316.16
2025-09-08ADPT-2.38-2.276.16
2025-09-09ADPT-2.38-2.276.16
2025-09-10ADPT-2.38-2.276.16
2025-09-11ADPT-2.38-2.275.80
2025-09-12ADPT-2.38-2.275.80
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.17

Avg. EPS Est. Current Quarter

-0.18

Avg. EPS Est. Next Quarter

-0.17

Insider Transactions

-2.38

Institutional Transactions

-2.27

Beta

2.05

Average Sales Estimate Current Quarter

58

Average Sales Estimate Next Quarter

63

Fair Value

Quality Score

39

Growth Score

47

Sentiment Score

71

Actual DrawDown %

82.3

Max Drawdown 5-Year %

-96.6

Target Price

14

P/E

Forward P/E

PEG

P/S

9.36

P/B

10.68

P/Free Cash Flow

EPS

-0.81

Average EPS Est. Cur. Y​

-0.72

EPS Next Y. (Est.)

-0.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-59.07

Relative Volume

0.93

Return on Equity vs Sector %

-92.3

Return on Equity vs Industry %

-79.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.12

EBIT Estimation

Adaptive Biotechnologies Corpor
Sector: Healthcare
Industry: Biotechnology
Employees: 619
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
stock quote shares ADPT – Adaptive Biotechnologies Corporation Stock Price stock today
news today ADPT – Adaptive Biotechnologies Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch ADPT – Adaptive Biotechnologies Corporation yahoo finance google finance
stock history ADPT – Adaptive Biotechnologies Corporation invest stock market
stock prices ADPT premarket after hours
ticker ADPT fair value insiders trading